Aspen Neuroscience closed a $115 million Series C to advance clinical development and scale manufacturing for ANPD001, its autologous iPSC‑derived cell therapy for Parkinson’s disease, and to expand its pipeline of personalized regenerative programs. ANPD001 holds FDA Fast Track designation and Aspen reported promising six‑month safety and efficacy signals from early cohorts. The financing will fund ongoing Phase I/IIa Cohort 3 dosing, commercial‑formulation development, manufacturing automation and pipeline expansion. Aspen highlighted a manufacturing platform that couples machine learning and genomics to produce patient‑specific cells without chronic immunosuppression. Investors framed the round as a bet on personalized regenerative medicine, while the company noted the need to demonstrate durability, scale‑up reproducibility and cost containment as it transitions from proof‑of‑concept to later‑stage trials.